NO20072541L - Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster - Google Patents

Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster

Info

Publication number
NO20072541L
NO20072541L NO20072541A NO20072541A NO20072541L NO 20072541 L NO20072541 L NO 20072541L NO 20072541 A NO20072541 A NO 20072541A NO 20072541 A NO20072541 A NO 20072541A NO 20072541 L NO20072541 L NO 20072541L
Authority
NO
Norway
Prior art keywords
crf
receptor antagonists
pyrazole
alpha
releasing factor
Prior art date
Application number
NO20072541A
Other languages
English (en)
Norwegian (no)
Inventor
Zhiyong Luo
John Edward Tellew
Xiaohu Zhang
Marion Lanier
Manisha Moorjami
Original Assignee
Sb Pharmco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35395069&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072541(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sb Pharmco Inc filed Critical Sb Pharmco Inc
Publication of NO20072541L publication Critical patent/NO20072541L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36Opioid-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20072541A 2004-10-19 2007-05-16 Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster NO20072541L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62006004P 2004-10-19 2004-10-19
GBGB0519957.5A GB0519957D0 (en) 2005-09-30 2005-09-30 Chemical compound
PCT/US2005/037576 WO2006044958A1 (en) 2004-10-19 2005-10-19 Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists

Publications (1)

Publication Number Publication Date
NO20072541L true NO20072541L (no) 2007-06-25

Family

ID=35395069

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20072541A NO20072541L (no) 2004-10-19 2007-05-16 Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster
NO20081941A NO20081941L (no) 2005-09-30 2008-04-23 Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister

Family Applications After (1)

Application Number Title Priority Date Filing Date
NO20081941A NO20081941L (no) 2005-09-30 2008-04-23 Pyrazol [1,5-alfa]pyrimidinylderivater nyttige som kortikotropin-frigivende faktor (CRF) reseptorantagonister

Country Status (21)

Country Link
US (1) US7879862B2 (ko)
EP (2) EP1802627B1 (ko)
JP (2) JP4901744B2 (ko)
KR (2) KR20070088621A (ko)
CN (1) CN101273043B (ko)
AR (2) AR051461A1 (ko)
AU (2) AU2005295353B2 (ko)
BR (1) BRPI0616767A2 (ko)
CA (2) CA2584567C (ko)
CR (1) CR9918A (ko)
EA (1) EA200801000A1 (ko)
GB (1) GB0519957D0 (ko)
IL (1) IL190225A0 (ko)
MA (1) MA29850B1 (ko)
NO (2) NO20072541L (ko)
NZ (1) NZ554082A (ko)
PE (2) PE20060586A1 (ko)
RU (1) RU2007118683A (ko)
TW (2) TW200626599A (ko)
UA (1) UA92756C2 (ko)
WO (2) WO2006044958A1 (ko)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7196078B2 (en) 2002-09-04 2007-03-27 Schering Corpoartion Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors
WO2005063755A1 (en) * 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7579360B2 (en) 2005-06-09 2009-08-25 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
US7572807B2 (en) 2005-06-09 2009-08-11 Bristol-Myers Squibb Company Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors
US8088779B2 (en) 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US8119658B2 (en) 2007-10-01 2012-02-21 Bristol-Myers Squibb Company Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
NZ586662A (en) 2007-12-19 2012-08-31 Vertex Pharma PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
CN102007133B (zh) * 2008-04-15 2013-06-12 卫材R&D管理有限公司 3-苯基吡唑并[5,1-b]噻唑化合物
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
AR078521A1 (es) * 2009-10-08 2011-11-16 Eisai R&D Man Co Ltd Compuesto pirazolotiazol
JPWO2011043387A1 (ja) * 2009-10-08 2013-03-04 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロオキサゾール化合物
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー CRF−1受容体アンタゴニストとしてのピラゾロ[5,1b]オキサゾール誘導体
ES2527849T3 (es) * 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
AR086554A1 (es) 2011-05-27 2014-01-08 Novartis Ag Derivados de la piperidina 3-espirociclica como agonistas de receptores de la ghrelina
WO2013074641A1 (en) 2011-11-16 2013-05-23 Array Biopharma Inc. Piperidinyl- substituted cyclic ureas as gpr119 modulators
JP2015516979A (ja) * 2012-04-23 2015-06-18 ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーHolsboermaschmeyer Neurochemie Gmbh Crh過剰活性を有する患者の治療に用いるためのcrhr1アンタゴニスト
EP2852591A1 (en) 2012-05-03 2015-04-01 Novartis AG L-malate salt of 2, 7 - diaza - spiro [4.5]dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
GB201210686D0 (en) 2012-06-15 2012-08-01 Holsboermaschmeyer Neurochemie Gmbh V1B receptor antagonist for use in the treatment of patients having an elevated AVP level and/or an elevated copeptin level
GB201310782D0 (en) 2013-06-17 2013-07-31 Max Planck Innovation Gmbh Method for predicting a treatment response to a CRHR1 antagonist and/or V1B antagonist in a patient with depressive and/or anxiety symptoms
WO2015112642A1 (en) 2014-01-21 2015-07-30 Neurocrine Biosciences, Inc. Crf1 receptor antagonists for the treatment of congenital adrenal hyperplasia
CA2935658C (en) * 2014-01-22 2023-02-21 Apodemus Ab Pyrazolo[1,5-a]pyrimidin-7-amine derivatives useful in therapy
JP7185633B2 (ja) 2017-02-17 2022-12-07 トレベナ・インコーポレイテッド 7員アザ複素環を含有するデルタ-オピオイド受容体調節化合物、その使用方法及び製造方法
WO2018165520A1 (en) 2017-03-10 2018-09-13 Vps-3, Inc. Metalloenzyme inhibitor compounds
JP2023508907A (ja) 2019-12-20 2023-03-06 テナヤ セラピューティクス, インコーポレイテッド フルオロアルキル-オキサジアゾールおよびその使用
JP2023546729A (ja) * 2020-10-27 2023-11-07 トレベナ・インコーポレイテッド デルタオピオイドモジュレーターの結晶形及び非晶形

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605642A (en) 1984-02-23 1986-08-12 The Salk Institute For Biological Studies CRF antagonists
KR100315837B1 (ko) 1994-06-21 2002-02-28 고리 히데아끼 피라졸로[1,5-a]피리미딘유도체
EP0880523B1 (en) 1996-02-07 2006-08-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as crf receptor antagonists
US6664261B2 (en) 1996-02-07 2003-12-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidines as CRF receptor antagonists
US6313124B1 (en) 1997-07-23 2001-11-06 Dupont Pharmaceuticals Company Tetrazine bicyclic compounds
ATE375344T1 (de) 1996-07-24 2007-10-15 Bristol Myers Squibb Pharma Co Azolotriazine und pyrimidine
NZ333777A (en) * 1996-07-24 2000-07-28 Du Pont Pharm Co (1,5-a) pyrazolo and triazole triazines and pyrimidines
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
JPH10101672A (ja) 1996-08-06 1998-04-21 Otsuka Pharmaceut Factory Inc アデノシン増強剤
JPH10101671A (ja) 1996-08-08 1998-04-21 Otsuka Pharmaceut Factory Inc 一酸化窒素合成酵素阻害剤
CA2263566C (en) 1996-08-28 2003-09-09 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
NZ505079A (en) * 1998-01-28 2003-08-29 Du Pont Pharm Co Pyrazolotriazines and pyrazolopyrimidines useful as corticotropin releasing factor antagonists
JP2000038350A (ja) 1998-05-18 2000-02-08 Yoshitomi Pharmaceut Ind Ltd 糖尿病治療薬
AU2321000A (en) 1999-01-29 2000-08-18 Sumitomo Chemical Company, Limited Fat accumulation inhibitory agents
WO2000059908A2 (en) * 1999-04-06 2000-10-12 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
ES2277855T3 (es) * 1999-09-30 2007-08-01 Neurogen Corporation Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas.
US6372743B1 (en) 1999-09-30 2002-04-16 Neurogen Corporation Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines
CO5271670A1 (es) * 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
HUP0304054A2 (hu) * 2001-04-30 2004-04-28 Glaxo Group Limited A kortikotropin-realising faktor (CRF) antagonistáiként alkalmazható kondenzált pirimidinek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
JP2004533465A (ja) * 2001-06-12 2004-11-04 グラクソ グループ リミテッド コルチコトロピン放出因子アンタゴニスト
GB0117396D0 (en) 2001-07-17 2001-09-05 Glaxo Group Ltd Chemical compounds
AU2003240488A1 (en) 2002-06-04 2003-12-19 Neogenesis Pharmaceuticals, Inc. Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents
JP2006515334A (ja) * 2003-01-16 2006-05-25 エスビー ファームコ プエルト リコ インコーポレーテッド CRF受容体アンタゴニストとしてのヘテロアリール置換ピロロ[2,3−b]ピリジン誘導体
EP1608652A1 (en) 2003-03-31 2005-12-28 Vernalis (Cambridge) Limited Pyrazolopyrimidine compounds and their use in medicine
US20070021429A1 (en) * 2003-04-09 2007-01-25 Yves St-Denis Condensed n-heterocyclic compounds and their use as crf receptor antagonists
GB0308208D0 (en) * 2003-04-09 2003-05-14 Glaxo Group Ltd Chemical compounds
WO2005063755A1 (en) 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
WO2005063756A1 (en) 2003-12-22 2005-07-14 Sb Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
DE102004008807A1 (de) * 2004-02-20 2005-09-08 Bayer Cropscience Ag Pyrazolopyrimidine
ATE430746T1 (de) * 2004-10-19 2009-05-15 Smithkline Beecham Cork Ltd Crf-rezeptor-antagonisten und zugehörige verfahren
GB0519957D0 (en) * 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US8088779B2 (en) * 2005-09-30 2012-01-03 Smithkline Beecham (Cork) Limited Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (CRF) receptor antagonists

Also Published As

Publication number Publication date
RU2007118683A (ru) 2008-11-27
WO2006044958A8 (en) 2006-06-08
NZ554082A (en) 2010-12-24
WO2007039264A1 (en) 2007-04-12
EP1934222B1 (en) 2012-07-25
CA2584567A1 (en) 2006-04-27
MA29850B1 (fr) 2008-10-03
CA2584567C (en) 2013-04-30
EP1802627A1 (en) 2007-07-04
EA200801000A1 (ru) 2009-02-27
PE20070845A1 (es) 2007-08-25
AU2006298995A1 (en) 2007-04-12
KR20070088621A (ko) 2007-08-29
WO2006044958A1 (en) 2006-04-27
JP4901744B2 (ja) 2012-03-21
CA2624699A1 (en) 2007-04-12
TW200626599A (en) 2006-08-01
PE20060586A1 (es) 2006-09-20
GB0519957D0 (en) 2005-11-09
EP1934222A1 (en) 2008-06-25
US20080194589A1 (en) 2008-08-14
AU2005295353B2 (en) 2012-01-12
NO20081941L (no) 2008-04-23
AU2005295353A1 (en) 2006-04-27
AU2006298995B2 (en) 2012-06-14
TW200745121A (en) 2007-12-16
IL190225A0 (en) 2009-09-22
AR051461A1 (es) 2007-01-17
JP2008517067A (ja) 2008-05-22
JP2009510004A (ja) 2009-03-12
BRPI0616767A2 (pt) 2011-06-28
CN101273043B (zh) 2011-08-03
KR20080063760A (ko) 2008-07-07
EP1802627B1 (en) 2012-08-29
CN101273043A (zh) 2008-09-24
US7879862B2 (en) 2011-02-01
UA92756C2 (ru) 2010-12-10
AR056104A1 (es) 2007-09-19
CR9918A (es) 2009-02-03

Similar Documents

Publication Publication Date Title
NO20072541L (no) Pyrazol[1,5-alfa]pyrlmldinylderivater anvendelige som kortlkotropin-frlglvende faktor (CRF) receptorantagonlster
WO2006044821A8 (en) Crf receptor antagonists and methods relating thereto
NO20063230L (no) CRF receptorantagonister og fremgangsmater for fremstilling derav
JO2676B1 (en) Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
MX2007007220A (es) Compuestos de pirazolona como agonistas de receptor de glutamato metabotropico para el tratamiento de trastornos neurologicos y psiquiatricos.
MY142090A (en) Substituted diaza-spiro-[5.5]-undecane derivatives and their use as neurokinin antagonists
TNSN05252A1 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders : process for their preparation and pharmaceutical compositions containing them
WO2007096782A3 (en) Compositions for disorders associated wtth metachromatic cell activation
NO20051100L (no) Pyrazolsammensetninger anvendelige som GSK-3-inhibitorer
WO2006007540A3 (en) Piperidine derivatives as nk1 antagonists
TW200606151A (en) Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
GB0508471D0 (en) Therapeutic agents
NO20081569L (no) Administrasjon av dipeptidylpeptildaseinhibitorer
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
WO2005103039A8 (en) 2- (3-aminopyrrolidin-1-yl) pyridines as melanin-concentrating hormone receptor an tagonists
NO20091489L (no) Tiazolpyrazolopyridiner som CRF1 reseptorantagonister
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
NO20091590L (no) Heterocykliske amidforbindelser anvendbare som kinaseinhibitorer
WO2007039781A3 (en) 1,2,4-oxadioi.e derivatives with activity at the metabotropic clutamate receptors
WO2007053495A3 (en) Compounds useful as antagonists of ccr2
JO2525B1 (en) Derived 4-alkyl-and-4-canoelperidine derivatives and their use as anti-neroquin
NO20090779L (no) 5,6-bisaryl-2-pyridin-karboksamidderivater, fremstilling og anvendelse derav i terapeutika som uretosin II receptorantagonister
WO2006094934A8 (en) Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
TW200704633A (en) Process for the preparation of sulfonamide derivatives
WO2009034029A3 (de) 1-substituierte 4 -heterocyclylpiperidine als cgrp antagonisten

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application